Description: Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Home Page: www.bonebiologics.com
BBLG Technical Analysis
2 Burlington Woods Drive
Burlington,
MA
01803
United States
Phone:
781 552 4452
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey Frelick | CEO & Pres |
| Ms. Deina H. Walsh | Chief Financial Officer |
| Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9268 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-03-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |